



(51) International Patent Classification:

C07D 471/04 (2006.01) *A61P 3/00* (2006.01)
A61K 31/437 (2006.01) *A61P 17/00* (2006.01)
A61P 29/00 (2006.01) *A61P 11/00* (2006.01)

(21) International Application Number:

PCT/US2012/052621

(22) International Filing Date:

28 August 2012 (28.08.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/530,028 1 September 2011 (01.09.2011) US

(71) Applicant (for all designated States except US): **IRM LLC** [US/US]; 131 Front Street, P.O. Box HM 2899, Hamilton, HM LX (BM).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **YEH, Vince** [CA/US]; 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **LI, Xiaolin** [CN/US]; 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **LIU, Xiaodong** [CN/US]; 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **LOREN, Jon** [US/US]; 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **MOLTENI, Valentina** [US/US]; 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **NABAKKA, Juliet** [US/US]; 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **NGUYEN, Bao** [US/US]; 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). **PETRASSI, Hank Michael James** [US/US]; 10675 John Jay Hopkins Drive, San Diego, California 92121 (US).

(74) Agents: **RAYMOND, Daniel E.** et al.; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))


Published:

- with international search report (Art. 21(3))

(54) Title: COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS



Formula (I)



Formula (II)

(57) Abstract: The invention provides compounds of formulae (I) and (II) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFR α , PDGFR β) kinases.